Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Allogene Therapeutics, Inc. - Common Stock
(NQ:
ALLO
)
1.340
-0.030 (-2.19%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Vail Resorts, Carnival, Opera And Other Big Stocks Moving Lower On Friday
↗
September 29, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session. Corcept Therapeutics Incorporated (NASDAQ: CORT) shares...
Via
Benzinga
Topics
Stocks
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
September 27, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Analyst Ratings for Allogene Therapeutics
↗
September 25, 2023
Via
Benzinga
Allogene Therapeutics Announces Participation in September Investor Conference
September 05, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Earnings Outlook For Allogene Therapeutics
↗
August 01, 2023
Via
Benzinga
Analyst Ratings for Allogene Therapeutics
↗
June 16, 2023
Via
Benzinga
Why Allogene Stock Is Trading Down Today
↗
June 14, 2023
Allogene Therapeutics, Inc. (NASDAQ: ALLO) shares are trading lower after the company announced its CFO Eric Schmidt will step down from his position.
Via
Benzinga
The Next Meme Stock: 6 Tickers Leading a Meme Stock Revival
August 18, 2023
Meme stocks soared during the early days of the pandemic. Will these stocks form a major meme stock rally or a short-lived farewell tour? Learn more.
Via
MarketBeat
Allogene Therapeutics Appoints Earl Douglas as General Counsel
August 14, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
August 02, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Where Allogene Therapeutics Stands With Analysts
↗
May 26, 2023
Via
Benzinga
The Latest Analyst Ratings for Allogene Therapeutics
↗
May 04, 2023
Via
Benzinga
Recap: Allogene Therapeutics Q1 Earnings
↗
May 03, 2023
Via
Benzinga
3 Stocks With Sky-High Short Interest Levels
July 31, 2023
BYND, BTAI, and ALLO stand out as high short-interest stocks to watch due to their potential for price fluctuations and short-squeeze opportunities.
Via
MarketBeat
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
July 26, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Short Squeeze Alert: The 5 Most Shorted Stocks Right Now
↗
June 22, 2023
Wondering what are the most shorted stocks this year? Here are the top five companies investors are betting against.
Via
InvestorPlace
Allogene Therapeutics' Allogeneic CAR-T Therapy Proves Potential for LBCL Treatment, Analysts See Potential for First-in-Class Status
↗
June 16, 2023
Thursday, Allogene Therapeutics Inc (NASDAQ: ALLO) presented the updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in 33 CAR T naïve patients with relapsed/refractory (r/r) large...
Via
Benzinga
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
June 15, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
June 14, 2023
Via
Benzinga
Allogene Therapeutics Announces Departure of Chief Financial Officer
June 14, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Why MIND Technology Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
↗
June 14, 2023
Gainers WeTrade Group, Inc. (NASDAQ: WETG) shares climbed 140.3% to $20.28. WeTrade launched large-scale language processing models to increase product applications in the field of artificial...
Via
Benzinga
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
June 09, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
May 24, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
The 3 Best Stocks to Short in May 2023
↗
May 19, 2023
The best stocks to short are companies whose businesses aren’t faring well and have a higher-than-average short interest.
Via
InvestorPlace
7 Short-Interest Stocks to Target for Explosive Gains
↗
May 18, 2023
For contrarian investors that can stand the heat, short-interest stocks to buy can offer significant rewards in a short time period.
Via
InvestorPlace
As Feinstein Returns To Congress, Reports Of Her Stock Profits Upset Aaron Rodgers
↗
May 15, 2023
Sen. Dianne Feinstein of California, one of the wealthiest members of Congress, continues to draw ire for her questionable stock trading while in office. What Happened: Feinstein, 89, "has some of the...
Via
Benzinga
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
May 11, 2023
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Zillow, Shopify, Datadog And Other Big Stocks Moving Higher On Thursday
↗
May 04, 2023
U.S. stocks traded lower, with the Dow Jones falling around 400 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Why Synaptics Shares Are Trading Lower By 17%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
May 04, 2023
Gainers Qurate Retail, Inc. (NASDAQ: QRTEB) shares jumped 89.3% to $7.44.
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
